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A B S T R A C T
Adult T-cell leukemia/lymphoma has a unique relationship to bone including latency in the marrow, and de-
velopment of bone invasion, osteolytic tumors and humoral hypercalcemia of malignancy. To study these
conditions, we established and characterized a novel mouse model of ATL bone metastasis. Patient-derived ATL
cell lines including three that do not express HTLV-1 oncoprotein Tax (ATL-ED, RV-ATL, TL-Om1), an in vitro
transformed human T-cell line with high Tax expression (HT-1RV), and an HTLV-1 negative T-cell lymphoma
(Jurkat) were injected intratibially into NSG mice, and were capable of proliferating and modifying the bone
microenvironment. Radiography, μCT, histopathology, immunohistochemistry, plasma calcium concentrations,
and qRT-PCR for several tumor-bone signaling mRNAs were performed. Luciferase-positive ATL-ED bone tumors
allowed for in vivo imaging and visualization of bone tumor growth and metastasis over time. ATL-ED and HT-
1RV cells caused mixed osteolytic/osteoblastic bone tumors, TL-Om1 cells exhibited minimal bone involvement
and aggressive local invasion into the adjacent soft tissues, Jurkat cells proliferated within bone marrow and
induced minimal bone cell response, and RV-ATL cells caused marked osteolysis. This mouse model revealed
important mechanisms of human ATL bone neoplasms and will be useful to investigate biological interactions,
potential therapeutic targets, and new bone-targeted agents for the prevention of ATL metastases to bone.
1. Introduction
Adult T-cell leukemia/lymphoma (ATL) is an aggressive hematolo-
gical malignancy of CD4+ T-lymphocytes that develops in 2–5% of
human T-cell leukemia virus type 1 (HTLV-1)-infected individuals
[1–3]. ATL develops after a 20–40 year latency and is associated with a
poor prognosis. About half of the acute ATL patients develop humoral
hypercalcemia of malignancy (HHM) due to increased tumor-induced
osteoclast activity and pathologic bone resorption [4–8]. Transcrip-
tional activator from the X region (Tax) and HTLV-1 basic zipper pro-
tein (Hbz) are critical regulatory genes in HTLV-I. Tax is a viral onco-
gene that regulates the transcriptional activity of the virus, while HBZ
antagonizes Tax and promotes proliferation of infected cells [9]. In
patients with ATL, especially those with the acute and lymphoma
subtypes, serum levels of tumor-produced, bone acting factors, such as
parathyroid hormone-related protein (PTHrP), CeC motif chemokine
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ligand 3 (CCL3/MIP-1α), interleukin-1 (IL-1), interleukin-6 (IL-6) and
receptor activator of nuclear factor kappa-Β ligand (RANKL) are in-
creased [8,10,11]. The expression profile of osteolytic signals is vari-
able between ATL patients with bone lesions resulting in a spectrum of
tumor-bone phenotypes [10–13]. The enhanced pathologic bone re-
sorption in ATL patients is primarily controlled through humoral or
endocrine-mediated mechanisms. However, several case reports have
identified primary ATL bone tumors that also express osteoclast sti-
mulatory factors, indicating a paracrine role for ATL factors in bone as
well [14–16]. Few studies have focused on the mechanisms by which
humoral or paracrine tumor-growth factors and cytokines from ATL
cells induce osteolysis and promote tumor progression.
The bone microenvironment is complex and consists of cells that
foster a fertile site for primary and metastatic bone tumors. These cells
include hematopoietic precursors, bone marrow stromal cells (BMSC),
endothelial cells, osteocytes, osteoblasts (OB), and osteoclasts (OC), all
of which may be influenced by tumor cells to induce bone into a pro-
tumorigenic microenvironment. Once tumor cells seed within the bone
marrow, tumor-derived factors (such as PTHRP) upregulate RANKL on
OBs which enhances RANK-RANKL signaling, OC differentiation and
activation, and subsequent bone resorption. This mechanism, among
others, disrupts the normal bone remodeling process resulting in
breakdown of mineralized bone matrix and release of growth factors
that promote tumor growth. Bone factors released include transforming
growth factor-β (TGF-β), insulin-like growth factors (IGFs), and bone
morphogenetic proteins (BMPs), which promote tumor growth and in-
crease the production of bone-acting factors from tumor cells. This
phenomenon is known as the ‘vicious cycle’ [17,18]. Crosstalk between
cancer and bone cells has been extensively studied in common bone-
metastatic tumors, such as multiple myeloma and breast cancer. How-
ever, the interactions between bone and ATL cells remain largely un-
known.
Animal models for hematological malignancies that involve bone
are necessary for investigation of the molecular and cellular mechan-
isms of cancer and bone cell interactions and are critical for bench-to-
bedside research. The phenotypic diversity of tumor-bone interactions
in patients is complex, therefore, multiple animal models will be re-
quired to recapitulate unique components of specific tumor types.
Xenograft mouse models of tumors in bone have utilized several ap-
proaches, including direct inoculation into bone or spontaneous osseous
spread after intracardiac injection. In this study, we have employed
direct intratibial injection to model tumor-bone interactions without
considering aspects of metastatic spread to bone, which are less re-
levant for hematologic malignancies that have ready access to the bone
as they circulate. The five cell lines characterized in this study differ in
their expression of the HTLV-1 oncogenes Tax and Hbz and demon-
strate significant phenotypic diversity. Thus, they provide a valuable
platform to explore tumor-bone signaling pathways and to elucidate
novel mechanisms by which ATL influences the bone microenviron-
ment.
2. Materials and methods
2.1. Reagents and cell lines
RV-ATL [19,20], ATL-ED [21,22], and TL-Om1 [23] cell lines were
derived from ATL patients. The HT-1RV cell line was developed by
superinfection of RV-ATL cells with HTLV-1 to create a cell line with
high-Tax expression [24]. The HT-1RV cell line was maintained in Is-
cove's medium (Corning, Manassas, VA, USA) supplemented with 10%
FBS, 2mM glutamine, 100 U/mL penicillin, and 100 µg/mL strepto-
mycin. HEK293T cells were maintained in DMEM medium (Invitrogen)
supplemented with 10% FBS, 2mM glutamine, 100 U/mL penicillin,
and 100 µg/mL streptomycin. The HTLV-1-negative T cell lymphoma
line (Jurkat), and ATL cell lines, ATL-ED, TL-Om1, and RV-ATL, were
cultured as previously described [21,25]. Briefly, Jurkat, ATL-ED and
TL-Om1 cells were cultured in RPMI 1640 medium supplemented with
10% fetal bovine serum (FBS) L-glutamine (2mM), penicillin (50 U/ml)
and streptomycin (50mg/ml) (Invitrogen). RV-ATL cells were passaged
in non-obese diabetic/ CB17-Prkdcscid (NOD/SCID) mice and briefly
cultured in the RPMI 1640 medium above supplemented with 20% FBS
prior to tibial injection.
2.2. Animals and inoculation
Male NSG (NOD-scid IL2Rgammanull) mice were acquired from the
NSG mouse colony maintained by the Target Validation Shared
Resource (TVSR) at the Ohio State University; breeders (Strain
#005557) for the colony were received from the Jackson laboratory.
Four- to five-week-old male NSG and NOD/SCID (NOD CB17-Prkdc-
SCID/J; The Jackson Laboratory, Bar Harbor, ME) mice were housed
and treated in accordance with the University Laboratory Animal
Resources guidelines, and experimental protocols were approved by the
Institutional Laboratory Animal Care and Use Committee. Intratibial
injections were performed to recapitulate bone tumors, as previously
described [26]. Briefly, mice were anesthetized in an induction
chamber with 3% isoflurane and maintained with 2.5% isoflurane. The
right rear limb was shaved with a disposable razor to remove the fur
and improve visibility. The distal leg was scrubbed with alcohol-soaked
gauze. The leg was held so the knee joint was at a 90° angle and a 27-ga,
½” needle was introduced through the patellar ligament and into the
tibial marrow space through the articular cartilage. A Hamilton syringe
was used to inject 10 µL containing 200,000–250,000 cells suspended in
RPMI 1640 medium (Iscove's medium for the HT-1RV cell line) into the
marrow cavity. Successful intratibial injections were verified by: (1) the
absence of joint invasion and lameness, (2) the absence of blockage or
resistance during the injection, (3) the absence of swelling or biolu-
minescence in the soft tissue surrounding the tibia after the injection
and (4) histopathological analysis at the end of the experiment de-
monstrating tumor cell invasion through the cortical bone. Mice were
euthanized 28–35 days after injection, except for the RV-ATL (38–43
days) and the ATL-ED-luc (20–29 days) mice.
2.3. Measurement of plasma calcium concentrations
Blood was collected using lithium heparin blood collection tubes
(Fisher Scientific). Blood was centrifuged and plasma was separated
and stored at −20 °C until measurements were performed. Total cal-
cium concentrations in plasma were measured using the QuantiChrom
Calcium Assay Kit (BioAssay Systems, Hayward, CA, USA).
2.4. Cytology, histopathology, immunohistochemistry, and enzymatic
histochemistry analysis
A complete necropsy was performed on each mouse. Impression
smears were made from the cut surfaces of the tumors, stained with
Modified Wright–Giemsa, and evaluated cytologically. Tibias and fe-
murs were removed, defleshed, and fixed in 10% neutral-buffered for-
malin (NBF) for 48 h. Tibias and femurs were placed in 70% ethanol for
24 h for μCT and faxitron imaging. After images were collected, tibias
and femurs were decalcified with mild Decalcifier (formaldehyde, me-
thanol and formic acid) (Leica Biosystems, Buffalo Grove, IL), em-
bedded in paraffin, sectioned and stained with H&E for histopathologic
evaluation. Femurs were processed similarly. Sections of liver, lung,
kidney, adrenal gland, spleen, and lymph node were fixed in 10% NBF
for 48 h, embedded in paraffin, sectioned, and stained with H&E for
histopathologic (micrometastasis) evaluation. Additional sections were
prepared for immunohistochemistry and enzymatic histochemistry.
Immunohistochemistry for human leukocyte antigen (1:100; Abcam,
Cambridge, MA, USA) was performed on paraffin-cut sections.
Enzymatic histochemistry for tartrate-resistant acid phosphatase
(TRAP) was performed to identify osteoclasts (Sigma-Aldrich, St. Louis,
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MO, USA) as previously described [27].
2.5. Radiographic imaging
Formalin-fixed tibias and femurs were soaked in ethanol for 48 h in
preparation for radiographic imaging. Tibias and femurs were placed
centrally on a Faxitron laboratory radiography system LX-60 (Faxitron
X-ray Corp., Wheeling, IL) imaging platform and high-resolution
radiographs were taken (for 2–6 s at 22–28 kV). The degree of radi-
olucency was used as a surrogate for bone loss and was quantified using
Bioquant Osteo 2010 software (Version 10.3.60MR). Radiograph
DICOM images were uploaded, the perimeter of each tibia was outlined
and areas were measured. Areas of radiolucency were then outlined and
measured for each tibia. Percent of tumor-associated bone loss was
calculated by dividing the area of radiolucency (bone loss) over the
measured total tibial area for each sample.
2.6. Microcomputed tomography (μCT)
Tibias were placed in a 17-mm holder and imaged using micro-
computed tomography (μCT) (μCT-40; Scanco Medical). The scanned
μCT DICOM images were imported into Inveon Research Workplace 3.0
software (Siemens Medical Solutions USA, Inc.) and a 3D-reconstruc-
tion model of the bone was built from 750 2D slices (0.8 mm) using
standard settings.
2.7. Transduction of ATL-ED cells for bioluminescent imaging
ATL-ED cells were selected for bioluminescent imaging to monitor
in vivo growth and spread. The pCDH-LTR-1-luc-EF1α-copGFP lentiviral
vector was described previously [28]. Briefly, HEK293T cells were
transfected with LTR-1-luc lentiviral vector plus DNA vectors encoding
HIV Gag/Pol and VSV-G in 10-cm dishes using Lipofectamine®2000
reagent according to manufacturer's instructions. Media containing the
lentiviral particles were collected 72 h later and filtered through 0.45-
μm-pore-size filters (Fisher Scientific). Lentiviral particles were then
concentrated using ultracentrifugation in a Sorvall SW-41 swinging
bucket rotor at 90,000 x g for 1.5 h at 4 °C. Target ATL-ED cells were
infected with concentrated, unselected LTR-1-luc lentivirus by spino-
culation at 2000 × g for 2 h at room temperature.
2.8. Bioluminescent imaging
Bioluminescent imaging of mice was performed using the IVIS 100
in vivo imaging system (Caliper Life Sciences) as previously described
[26]. Briefly, 0.15ml of sterile DPBS containing 4.5mg of D-luciferin
(Caliper Life Sciences, Hopkinton, MA) was injected intraperitoneally
and imaging was performed 5 min later. Serial images were taken every
2 min until peak photon emission was obtained (approximately 10 min
post-injection). Photon signal intensity was quantified using Living-
Image software version 2.50 (Caliper Life Sciences). Tumor growth was
determined based on change in total flux (photons/s) from day of in-
jection to day of sacrifice.
2.9. RNA extraction, reverse transcription, and real-time qRT-PCR
Immediately after the euthanasia of ATL xenografted mice, tumors
were carefully dissected from the tibias, snap frozen in liquid nitrogen
and stored at −80 °C until further use. Approximately 20–22mg of
tissue were resuspended in tissue RNA lysis buffer and RNA was iso-
lated using a QuickGene Mini 80 (Autogen). Reverse transcription
(cDNA) and quantitative real-time polymerase chain reaction (qRT-
PCR) were performed, as previously described [25,26,29]. qRT-PCR
was performed using human-specific oligonucleotide primers shown in
Table 1. These primers were designed and tested as described pre-
viously [26,30]. Relative gene expression was normalized to GAPDH
using the ΔΔCt method.
2.10. Statistical analysis
Data were analyzed using Graph Pad Prism 6.0 software (San Diego,
CA). Students t-test and analysis of variance (ANOVAs) were used for
statistical analysis. qRT-PCR values were normalized to GAPDH mRNA
and were expressed as the fold difference between the groups
(mean± SD). All cell lines were compared against ATL-ED cells in the
qRT-PCR graphs using a one-way ANOVA with Dunnett's multiple
comparison post hoc test. A p value ≤ 0.05 was considered to be sta-
tistically significant. Plasma calcium concentrations were analyzed
using a one-way ANOVA. For in vivo imaging data of ATL-ED xeno-
grafts, the average bioluminescence (photons/s/cm2) and corre-
sponding standard errors of the mean were determined for each ex-
periment. Quantitative radiographic bone loss determined in ATL
xenografts was analyzed statistically with a non-parametric
Kruskal–Wallis test.
3. Results
3.1. NSG mice demonstrated superior engraftment of ATL cell lines over
NOD/SCID
Two strains of immunosuppressed mice were selected for compar-
ison of tumor cell engraftment in order to optimize tibial injections.
Three cell lines were used in this comparison. The RV-ATL and TL-Om1
cell lines (neither express the oncogene Tax) and the HT-1RV cell line
(with high Tax mRNA expression) were selected for comparison of tibial
engraftment potential between NOD/SCID and NSG mice. The presence
or absence of Tax was considered because of its immunogenic potential.
Mice were sacrificed at various times (see Section 2) following in-
oculation, and gross tumor development was recorded. Engraftment of
all three cell lines was improved when injected intratibially into the
NSG mice compared to the NOD/SCID strain (Fig. 1). In particular, HT-
1RV cells went from 0% to 100% engraftment, indicating that Tax was
highly immunogenic in the NOD/SCID mice, probably because NOD/
SCID mice still have NK cells, while NSG mice do not [31]. None of the
NOD/SCID tumor-bearing mice had evidence of metastasis. Distant
metastasis was observed in the NSG mice bearing HT-1RV tumors.
These results are consistent with previous reports noting the advantage
in development of metastasis in xenografted NSG mouse models [32].
3.2. ATL cells engrafted following intratibial inoculation and some
developed metastases
Based on the findings above, we determined that the NSG mice were
the best strain of mice to use for this study. Thus, NSG mice were also
inoculated with ATL-ED and Jurkat cell lines. ATL-ED is another Tax-
negative cell line derived from an ATL patient and Jurkat is an HTLV-1-
negative T-cell lymphoma cell line that served as a control in our ex-
periments. The percent of tibial engraftment ranged from 62% (TL-
Om1; n=5/8, number of engraftments/number of injections), 71%
(RV-ATL; n=10/14), 73% (ATL-ED; n=25/34, including ATL-ED-luc
injections), 75% (HT-1RV; n=6/8) to 100% for Jurkat (n=12/12)
cell lines in the NSG mice. The human origin of the xenografts was
confirmed using immunohistochemistry for human-specific leukocyte
antigen (Fig. 2). A summary of radiographic and histopathologic
characteristics of ATL tumor engraftment is provided in Table 2. Me-
tastasis occurred in mice with the ATL-ED and HT-1RV cell lines. ATL-
ED cells formed metastases in both the liver (Fig. 3) and kidney of 3
(out of 5) mice. HT-1RV tumor cells were present in the liver and brain
of three and one (out of 4) mice, respectively. Local invasion into the
adjacent soft tissues including the gastrocnemius muscle was con-
sistently observed in mice with TL-Om1 and RV-ATL cells. Jurkat tu-
mors crossed the joint space of the knee and grew in the ipsilateral
N.A. Kohart, et al. Journal of Bone Oncology 19 (2019) 100257
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femoral marrow cavity. This experiment showed that all of the ATL cell
lines consistently engraft following intratibial inoculation into NSG
mice, while some of them also metastasize occasionally to the liver,
kidney and brain.
3.3. Human ATL cells induce osteolytic bone destruction
Patients with ATL often have widespread osteolytic lesions and
hypercalcemia [8,33]. We evaluated ATL engrafted mice for osteolysis
and bone destruction using X-Ray and μCT scanning. Tibias with ATL-
ED tumors showed osteosclerosis (increased radiopacity) within the
proximal tibia with multifocal to punctate intralesional, radiolucent
areas (Fig. 4(A)), often extending from the proximal tibia to the mid
diaphyseal region, and occasionally to the distal diaphysis. In addition,
spicules of new bone extending from the proximal to mid-diaphyseal
periosteum were present, consistent with periosteal new bone forma-
tion (Fig. 4(A)). μCT imaging was consistent with the radiographic
findings and demonstrated marked irregular new bone in the marrow
cavity as well as on the periosteum (Fig. 6(A)). Similar radiographic and
μCT findings were observed in the HT-1RV bone tumors, although the
new bone, especially on the periosteum, was not as extensive (Figs. 4(B)
and 6(B)). In contrast, tibias with RV-ATL tumors primarily showed
bone loss characterized by focal, multifocal, to diffuse areas of radi-
olucency in the proximal tibia and the diaphysis (Fig. 4(C)). Quantifi-
cation of bone radiographs showed that the percent of total bone loss
per total bone volume was significantly greater in the tibias with RV-
ATL tumors compared to the tibias with other tumor types (Fig. 5). TL-
Om1 and Jurkat bone tumors demonstrated minimal radiographic
evidence of bone pathology, and tibial cortices were smooth and intact.
Slight changes in radiopacity and radiolucency were observed
(Fig. 4(D)–(E)). Despite minimal evidence of exterior bone pathology of
the TL-Om1 and Jurkat bone tumors on longitudinal μCT images
(Fig. 6(C)–(D), upper panels), significant differences were observed
within the proximal marrow cavity (lower panels). TL-Om1 bones had
little trabecular bone compared to Jurkat xenograft tibias, which had
moderate amounts of irregular cords of endosteal (intramedullary) new
bone extending from the inner cortex into the marrow cavity
(Fig. 6(C)–(D)). Blood was collected on the day of sacrifice for mea-
surement of plasma calcium levels. Interestingly, despite marked focal
bone resorption and remodeling in several ATL xenografts, plasma
calcium concentrations were within the reference range and were si-
milar among all the groups (data not shown), perhaps reflecting the
focal nature of bone involvement in this intratibial injection model.
3.4. Enhanced bone remodeling and bone destruction in ATL xenografts
Histopathology was performed on tibial tumors in order to examine
the bone remodeling and bone destruction phenotypes more closely.
H&E sections of ATL-ED tumor-bearing tibias revealed a large, mark-
edly atypical round cell population diffusely expanding the medullary
cavity, invading and destroying the cortical bone, and extending onto
the periosteal surface (Fig. 7(A)). The marrow was completely effaced
by tumor cells with coagulation necrosis, fibrosis, and marked en-
dosteal new woven bone formation that was characterized by high os-
teocyte density. Irregular spicules of woven bone were frequently seen
irradiating from the surface of cortical bone, consistent with periosteal
new bone formation. TRAP staining revealed low to moderate numbers
of TRAP-positive osteoclasts distributed along the periosteal new bone
surfaces and were rarely seen associated with the remaining trabecular
and cortical bone. Cytologic impression smears of ATL-ED tumor cells
revealed a large neoplastic round cell population with marked aniso-
cytosis and anisokaryosis. HT-1RV tumor cells effaced the bone marrow
cavity expanding longitudinally within the marrow and adjacent femur
and laterally through the cortical bone (Fig. 7(B)). In some mice there
was invasion into the joint capsule. Marked periosteal new bone for-
mation was present from the proximal tibia to the diaphysis. The
marrow had an atypical round to spindle-shaped tumor cell population
with regions of coagulation necrosis. Irregular cords of reactive murine
stromal cells were present spanning from the cortical and new trabe-
cular bone into the physis.
RV-ATL tumors effaced the marrow cavity, eroded through the bone
cortices, and aggressively invaded into the adjacent soft tissues. Marked
pathologic bone resorption was present involving cortices and cancel-
lous bone (Fig. 7(C)). Many large TRAP-positive osteoclasts were pre-
sent along cortical and trabecular bone surfaces. Additionally, osteo-
clasts were seen detached from trabecular bone surfaces and
intercalated among the RV-ATL cells and fibrostromal cells within the
medullary cavity (lower panel). The activity and number of osteoclasts
Table 1
Primers used for qRT-PCR of tumor samples.
Gene name Forward primer Reverse primer
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) GCAAATTCCATGGCACCGTC AGCATCGCCCCACTTGATTT
parathyroid hormone-related protein (PTHrP) GTCTCAGCCGCCGCCTCAA GGAAGAATCGTCGCCGTAAA
parathyroid hormone 1 receptor (PTH1R) GGCTTCACAGTCTTCGGCT GAGCACCCGGACGATATTGAT
C-C motif chemokine ligand 3 (CCL3) CTGCATCACTTGCTGCTGACA CACTGGCTGCTCGTCTCAAAG
colony stimulating factor 1 (CSF1) GCAGGAACTCTCTTTGAGGCT TCTTGACCTTCTCCAGCAACTG
lysophosphatidic acid receptor 1 (LPAR1) GTAGTTCTGGGGCGTGTTCA ACCAGCTTGCTGACTGTGTT
tumor necrosis factor (TNF) CCCTCTGGCCCAGGCAGTCA CGGCGGTTCAGCCACTGGAG
receptor activator of nuclear factor kappa-Β ligand (RANKL) CCTTTCAAGGAGCTGTGCAA CATCCACCATCGCTTTCTCT
Osteoprotegerin (OPG) GGCACCAAAGTAAACGCAGAG ACGCTGTTTTCACAGAGGTCA
Transcriptional activator from the X region (Tax) CCGCCGATCCCAAAGAAA CCGAACATAGTCCCCCAGA
HTLV-1 basic zipper protein (Hbz) AACTTACCTAGACGGCGGAC CATGGCACAGGCAAGCATCG.
Fig. 1. Tibial tumor engraftment of ATL cell lines in immunosuppressed mice.
Improved tumor engraftment in bone following intratibial injection of ATL cell
lines, RV-ATL (n=14 tibias in NSG mice, n=12 in NOD/SCID mice), HT-1RV
(n= 8 tibias for each mouse type), and TL-Om1 (n=8 tibias for each) in NSG
mice compared to NOD/SCID mice.
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in the RV-ATL tumors were increased compared to Jurkat tumors
(Fig. 8(A)–(D)). Cytologic evaluation of the RV-ATL cells revealed an
atypical round cell population with a high nuclear to cytoplasmic ratio.
The TL-Om1 cell line had regional invasion into the metaphysis and
diaphysis and also into the adjacent soft tissues surrounding the me-
taphysis through the ‘cut back’ zone of the cortex (Fig. 7(D)).
Osteoclasts, osteoblasts, and bone-lining cells were quiescent. Im-
pression smears of TL-Om1 tumors revealed a moderately atypical
round cell population characterized by a high nuclear to cytoplasmic
ratio.
Jurkat tumors proliferated within the medullary cavity of the tibias
and elicited minimal bone cell response. An atypical round cell
Fig. 2. Immunohistochemistry for human leukocyte antigen in ATL cells of a xenograft tibial tumor. ATL and Jurkat intratibial tumors were confirmed to be of human
origin by staining for HLA: (A) Jurkat cells (magnification=40X), (B) Jurkat (200X), (C) Jurkat (spleen, negative control, 100X), (D) HT1-RV cells (40X), (E) HT1-RV
(100X), (F) HT1-RV (spleen, 100X), (G) RV-ATL cells (40X), (H) ATL-ED cells (40X), (I) TL-Om1 cells (100X), (J) RV-ATL (100X), (K) ATL-ED (400X), (L) TL-Om1
(400X).
Table 2
In vivo characteristics and bone pathology of ATL models.
Cell line Origin Tax mRNA level Hbz mRNA level Osteolysis Osteosclerosis New bone Femur INV Skeletal Muscle INV Metastasis
RV-ATL L – + Marked Mild Mild +/− + –
HT-1RV L+ IT +++ ++ Moderate Moderate Moderate +/− + +
ATL-ED L – + Mild Marked Marked +/− + +
TL-Om1 L – + Mild Mild Mild − + –
Jurkat L – – Mild Mild Mild + – –
Tax and Hbz mRNA expression was measured by qRT-PCR (Fig. 10, +++ Crossing point (Cp)<20, ++ Cp=20–25,+ Cp=25–30, − Cp>30). The degree of
osteolysis was determined by calculating the percentage of bone loss on radiographs (Fig. 5, Mild=2.5–7.5% bone loss; Moderate=7.5–15%; Marked >15%).
Intramedullary osteosclerosis, periosteal new bone formation, adjacent femur and skeletal muscle invasion, and distant metastasis were evaluated by histopathology,
radiography and μCT imaging. *L, leukemic; IT, in vitro transformed; −, negative; +, positive; +/−, inconsistent but observed; INV, invasion.
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population diffusely expanded and replaced normal marrow con-
stituents (Fig. 7(E)) with regions of marrow necrosis. Despite the nu-
merous Jurkat cells within the bone, the cortices remained intact. Oc-
casional spicules of woven bone were seen extended into the center of
the marrow. The atypical tumor cells were present adjacent to the
preexisting trabeculae and coexisted with quiescent bone-lining cells,
OCs, and OBs (lower panel).
3.5. Bioluminescent imaging of ATL bone metastasis revealed visceral and
bone tumor growth
To monitor tumor progression and metastatsis, the ATL-ED cell line
was transduced with a firefly luciferase reporter. Bioluminescent ima-
ging was performed on the day of injection and was used to confirm
successful intratibial injections (Fig. 9(A)). Weekly imaging revealed an
increase in tumor growth and metastasis (Fig. 9(B)). Tibial tumor
growth rate was determined by measuring the average total flux
(photons/s) per tibia over the course of 24 days. There was an 84-fold
increase in ATL-ED-luc viable cell number from injection to the day of
sacrifice as determined by the change in total flux (Fig. 9(C)). Distant
metastases were observed in the liver (Fig. 3) and lung (Fig. 9(B)).
Therefore, the ATL-ED model can be used to investigate tumor-bone
interactions in the marrow, and distant metastases.
3.6. ATL xenograft phenotypic diversity was mirrored by diversity in mRNA
expression of tumor-related bone factors
Radiography and histopathology showed significant differences in
tumor-bone phenotypes in ATL xenograft mice. To investigate potential
mechanisms and signaling pathways involved, we measured several
pro- and anti-osteolytic tumor-associated mRNAs along with Tax and
Hbz in the ATL cell line xenografts using qRT-PCR and human-specific
primers (Fig. 10 and Table 1). RANKL is a key factor for the activation
of osteoclast differentiation and activation and its synthesis is triggered
by PTHRP stimulation of osteoblasts [34]. Osteoprotegerin (OPG) is
known as a decoy receptor for RANKL. LPAR1, TNF, CCL3, and CSF1
are factors also known to have a role in osteoclast differentiation and
activation in bone-tropic tumors. As expected, Tax mRNA was un-
detectable in all of our xenografts except HT-1RV, where it was ex-
pressed at high levels, while Hbz mRNA expression was moderate in the
ATL bone tumors, but >15-fold greater in the HT-1RV bone tumors.
HBZ expression was 1.5–3.1-fold higher in the bone tumors compared
to the original uninjected cell lines, while Tax expression was increased
∼2-fold in the HT1RV bone tumors (data not shown). With regard to
Fig. 3. Liver metastasis of ATL-ED intratibial xenograft. (A) There were metastases (white arrows) in the liver following intratibial injection of ATL-ED cells. (B) H&E-
stained slide of a liver micrometastasis (magnification=200X).
Fig. 4. Radiographs of ATL and Jurkat tibial
xenograft tumors. (A) ATL-ED tumors demon-
strated increased radiopacity (osteosclerosis)
within the proximal tibia and metaphysis, in
addition, new bone was present along the
caudal periosteum. (B) HT-1RV bone tumors
had increased radiopacity within the proximal
tibia with multifocal punctate radiolucent foci.
(C) RV-ATL tumors demonstrated large focal,
radiolucent areas within the proximal tibia
consistent with bone loss. (D) TL-Om1 bone
tumors revealed increased intramedullary
radiopacity with smooth, intact cortical sur-
faces. (E) Jurkat tumors demonstrated minimal
radiographic changes.
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the bone factors, RV-ATL xenografts expressed the highest of amount of
PTHRP, RANKL, and OPG mRNA. HT-1RV xenografts expressed the
highest of amount of parathyroid hormone/PTHRP receptor 1 (PTH1R),
CCL3 (MIP-1α), OPG, CSF1 and TNF mRNA. TL-Om1 xenografts ex-
pressed the highest of amount of LPAR1 mRNA. The differences in
mRNA expression between the different tumors was consistent with
their phenotypic diversity and sheds light into potential mechanisms
and signaling pathways involved.
4. Discussion
Several mouse models exist to study the pathogenesis of HTLV-1 and
ATL. Transgenic mice with HTLV-1-specific protein expression have
provided insight into the specific roles that Hbz and Tax play in the
development of leukemia/lymphoma, and HTLV-1-infected humanized
mice have been useful to investigate host responses in ATL and testing
of novel therapeutics [35–37]. While xenograft mouse models of ATL
have been used to investigate ATL tumor cell progression, invasion,
interaction with the microenvironment and paraneoplastic syndromes
[27,38], the availability of in vivo models to investigate ATL bone in-
teractions is limited. Given the significant impact that bone involve-
ment has on patient morbidity and resistance to chemotherapy, it
would be invaluable to have a reproducible animal model to elucidate
the tumor-bone interactions and investigate novel therapies for ATL in
bone. In this study, we established and characterized a novel mouse
model of ATL in bone. Due to the difficulty in assessing tumor burden
and progression in vivo, we successfully transduced an ATL cell line that
consistently results in pathologic tumor-induced bone changes with a
lentivirus containing the luciferase gene to allow for noninvasive tumor
detection and monitoring using bioluminescence.
The SCID mouse was developed in 1983 and was commonly used for
the transplantation of human cancer cells. These mice do not have
functional B or T cells, but do have residual natural killer (NK) cell
activity [39]. Refinement of this model resulted in the development of
the NOD/SCID mouse that has reduced NK cell activity [40–42]. Xe-
nograft studies in ATL have largely employed the NOD/SCID model
with a higher rate of ATL engraftment due to the reduced NK cell
function and the resulting inability of NOD/SCID mice to recognize and
eliminate Tax-expressing cells [19,40]. In recent years, xenograft suc-
cess of human cancer cell lines was further advanced with the advent of
the NSG mouse. These mice are based on the NOD/SCID background
and have a deletion in the gamma chain of the interleukin 2 receptor.
Fig. 5. Bone loss for ATL and Jurkat xenograft tibial tumors. The degree of
radiolucency was quantified on the radiographs of tumor-bearing tibias as de-
scribed in Methods. Jurkat, HT1-RV and TL-Om1 (n=4 tibias each), ATL-ED
(n=5 tibias), RV-ATL (n=6 tibias). The ‘*’ symbol represents a p value of less
than 0.05 as determined by one-way ANOVA. Tibias with RV-ATL tumors had
significantly greater bone loss per total bone volume when compared to other
ATL and Jurkat tumors.
Fig. 6. μCT 3D reconstructions of ATL and
Jurkat xenograft tibial tumors. Longitudinal
and transverse sections of μCT 3D reconstruc-
tions of tibias with ATL and Jurkat bone tu-
mors. (n=2 for each cell line) (A) ATL-ED-
bearing tibias had marked periosteal bone
formation spanning the medial and lateral re-
gion of the tibia. Transverse sections demon-
strated an increase in endosteal new bone (in-
tramedullary osteosclerosis) (lower panel). (B)
The HT-1RV-bearing tibias had an irregular
periosteal surface from the proximal meta-
physis to the distal diaphysis. Minimal
amounts of medullary bone were present in
tibias with HT-1RV tumors, indicative of in-
tramedullary bone loss (lower panel). (C)
Tibias from the TL-Om1-bearing mice had
minimal changes in the tibias; however, they
had decreased trabecular bone (lower panel).
(D) Tibias with Jurkat tumors had smooth ex-
ternal cortical surfaces with minimal evidence
of lysis or pathologic new bone formation.
Transverse sections of tibias with Jurkat tu-
mors had normal amounts of trabecular bone
(lower panel).
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This leads to a defect in the ability of dendritic cells to secrete inter-
feron-gamma (IFN-γ) when activated, causing a near complete ablation
of both innate and adaptive immunity that allows efficient human
tumor engraftment [43–45].We evaluated engraftment potential of ATL
cells in bone in the NOD/SCID and NSG strains. While tumor devel-
opment was observed with the TL-Om1 and RV-ATL intratibial injec-
tions in the NOD/SCID mice, the HT-1RV cell line, which expresses high
levels of Tax, failed to engraft in the NOD/SCID mice. This is consistent
with previous reports suggesting that Tax serves as a potent stimulus of
the immune response. All ATL lines, including HT1-RV, showed im-
proved engraftment in the more highly immunodeficient NSG strain.
While paraneoplastic bone loss is common in ATL patients, primary
ATL bone tumors resulting in local solitary or multiple lytic lesions also
have been described [14,27,46–49]. While the role of the endocrine
factors that mediate HHM and widespread bone resorption in ATL have
been investigated, the description of the direct interaction between ATL
and the cells of the bone microenvironment has largely been limited to
case reports. Bone lesions are observed in 5.5% of ATL patients, mainly
in the tibia, ulna, scapula, femur, clavicle, and peripheral extremities
[14,49,50]. Regardless of the presence or absence of tumor cells, bone
biopsies of ATL patients consistently demonstrate a marked increase in
number and activation of osteoclasts lining the bone trabeculae and
Fig. 7. Histopathology of ATL and Jurkat xenograft tibial tumors. Photomicrographs of H&E-stained tibias with ATL and Jurkat tumors. (A) ATL-ED bone tumors
were characterized by invasion through and resorption of the cortex with marked periosteal new bone formation. Coagulation necrosis, fibrosis, and osteosclerosis
were present throughout the medullary cavity with extensive tumor-induced new bone formation (lower panel). (B) New woven bone formation was present in HT-
1RV bone tumors extending from preexisting cortices into the medullary cavity. Reactive stromal cells were present and associated with the HT-1RV tumor cells
(lower panel). (C) Marked osteoclastic bone resorption was present in RV-ATL tumors characterized by extensive erosion of cortical and trabecular surfaces.
Hypertrophic osteoclasts were present admixed with tumor and stromal cells within the medullary cavity (lower panel). (D) Tibias of mice with TL-Om1 tumors had
minimal bone response. Despite the replacement of normal marrow constituents with tumor, minimal activation of osteoblasts and osteoclasts were observed on
trabeculae (lower panel). (E) Jurkat cells proliferated within the bone marrow and induced minimal bone cell response. Top panels (magnification=20X), lower
panels (400X).
Fig. 8. H&E and TRAP-stained images of os-
teoclast activity in RV-ATL and Jurkat xeno-
graft bone tumors. (A) There were markedly
hypertrophic osteoclasts lining trabecular bone
in an NSG mouse with an intratibial RV-ATL
tumor. (magnification=800X) (B) In contrast,
osteoclasts in NSG mice with Jurkat tumors
appeared normal with minimal activation.
(400X) (C) TRAP staining displayed increased
numbers of positively-stained hypertrophic
multinucleate osteoclasts lining the resorbed
bone surfaces in RV-ATL tumors. Osteoclasts
were also found surrounded by tumor cells.
(400X) (D) Positive TRAP staining of inactive
osteoclasts in Jurkat tumors were present on
the surfaces of trabecular bone. (200X).
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cortices, resulting in either local or systemic bone loss [1]. Osteoblast
activation and extensive fibrosis have also been described [1,51,52].
Osteoporosis, pathologic fractures, and primary confinement to the
marrow also have been observed in ATL patients, indicative of het-
erogeneity in the disease and its interaction with bone [15,16,53–55].
Our research using xenograft models of ATL interactions reproduces the
diversity of bone phenotypes observed in ATL patients. ATL-ED has a
predominantly osteoblastic pattern, with relatively little osteolysis, and
conversely RV-ATL is primarily osteolytic, while HT-1RV has a mixed
osteolytic/osteoblastic pattern. TL-Om1 shows diffuse marrow in-
volvement after implantation, but causes little change in bone struc-
ture.
To investigate potential factors and signaling pathways responsible
for the variety of bone phenotypes, qRT-PCR was performed on several
bone signaling mRNAs in ATL xenograft tumors. PTHrP stimulates the
shared parathyroid hormone/PTHRP receptor 1 (PTH1R), which is
found on osteoblasts, osteocytes, and their precursors. The effects of
PTH1R stimulation are context-dependent, and can result in the se-
cretion of factors that activate OCs and cause bone resorption [56–58],
as well as stimulating direct bone formation (add ref for anabolic role).
PTHRP is highly expressed in ATL patients with both hypercalcemia
and normocalcemia. Although the most osteolytic cell line, RV-ATL,
expressed the highest levels of PTHrP, this factor was also increased in
TL-Om1, which did not show osteolysis, and all of our models were
normocalcemic. The lack of elevation in serum calcium may be due to
the focal nature of bone involvement in this direct inoculation protocol.
A potential autocrine role for PTHRP in HTLV-I transformation has also
been described [59,60]. HT-1RV was the only model that showed high
expression of PTH1R, as well as some PTHrP, which could allow au-
tocrine signaling. Since the expression of PTHrP alone does not directly
correlate with the ATL effects on bone, it is likely other tumor-derived
factors are also important.
We analyzed the expression of several bone signaling mRNAs by
qRT-PCR (Fig. 10). Each of the cell lines had a different pattern of ex-
pression of these mRNAs. The variation in tumor expression of bone-
acting factors suggests that there is no single mediator of ATL effects on
bone, and this panel of models could be useful to delineate the range of
factors potentially involved. The ATL cell line with the greatest extent
of osteolytic bone resorption and destruction was the RV-ATL tibial
xenograft, which also had the highest expression of PTHrP and RANKL
mRNA. RV-ATL cells also had increased expression of OPG compared to
ATL-ED and TL-Om1, but this amount paled in comparison to the
amount of RANKL that was expressed and, thus, it is unlikely to play a
significant role in the RV-ATL bone phenotype.
HT-1RV cells were derived from RV-ATL cells by superinfection
with HTLV-1. Tax is silenced (5′ deletion, hypermethylation, mutation)
in the majority of ATL patients, while Hbz is expressed in most ATL
patients. HT-1RV expressed very high levels of Tax mRNA (similar to
GAPDH mRNA levels), whereas the other three cell lines expressed
essentially undetectable amounts of Tax mRNA. Hbz mRNA was already
expressed at moderate levels in the ATL cell lines, but it was increased
an additional 24-fold in HT-1RV cells. In addition, PTHRP and RANKL
were significantly downregulated (10- and 140-fold, respectively) in
HT-1RV compared to RV-ATL xenografts, with no change in the amount
of OPG mRNA. It is possible that PTHRP and RANKL were primarily
responsible for the high level of bone loss in RV-ATL xenografts, com-
pared to the moderate bone loss that in HT-1RV xenografts. However,
several osteolytic factors were higher in HT-1RV [CCL3 (7-fold), CSF1
(25-fold) and/or TNF (770-fold)] again indicating that simply evalu-
ating particular factors is unlikely to reflect the complex biology of the
bone microenvironment and its response to tumors.
Tumors derived from TL-Om1 cells, which caused little change in
the bone, also showed low expression of osteolytic factors, except for
LPAR1. ATL-ED tumors were the most osteosclerotic of the tumors and
had a low amount of bone loss. Therefore, it was not surprising that
ATL-ED tumors expressed the lowest amount of each of the osteolytic
mRNAs that were examined. Further work is required to define the
factors/pathways that are involved in the increased periosteal new
bone and intramedullary osteosclerosis of ATL-ED xenografts.
In conclusion, we report the generation and characterization of a
novel ATL bone tumor model. The variation in tumor-bone phenotypes
observed with the different cell lines illustrates the complexity of
Fig. 9. In vivo bioluminescent imaging of tumor growth and progression of the
ATL-ED intratibial xenograft model. The highest level of photon emission cor-
responded to the red end of the color spectrum. (A) Bioluminescent imaging
performed on the day of injection confirmed correct intratibial injections as
noted by photon signals in both left and right tibias and in the lungs (indicative
of tumor cells in the vasculature). (B) Fourteen days following injection photon
intensity was increased, correlating with progressive growth of ATL-ED tumors.
In addition, some of the mice displayed distant metastases (black arrowheads)
(C) The photon emission of each tibia of ATL-ED-luc mice was identified as the
region of interest. Total flux (photons/s) was calculated for each region of in-
terest and averaged. There was an 84-fold increase in ATL-ED-luc tumor growth
at 24 days following injection. Week 1 (n=14 tibias), week 2 (n=12), week 4
(n=6).
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Fig. 10. qRT-PCR of viral and bone-sig-
naling mRNAs in ATL xenograft bone tu-
mors. To investigate signaling pathways
and factors responsible for the variation in
tumor-bone phenotypes, qRT-PCR was
performed on several bone signaling
mRNAs in ATL xenograft tumors. The
variation in tumor expression of bone-
acting factors reflected the heterogeneity
observed in the tumor-bone phenotypes of
ATL intratibial xenograft mice. Since ATL-
ED xenografts expressed the lowest
amounts of most of the mRNAs examined,
all the other cell lines were compared
against ATL-ED. RV-ATL (n=3 tumor
samples), HT1-RV (n=4), ATL-ED
(n=5), TL-Om1 (n=6). A one-way
ANOVA test was used for statistical com-
parison and the ‘*’ symbol indicates a p
<0.05; ‘**’ symbol indicates a p <0.01;
‘***’ symbol indicates a p <0.001; ‘****’
symbol indicates a p <0.0001.
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tumor-bone pathobiology. For example, if an investigator wants to
study the osteoblastic component of ATL, the ATL-ED cells will be the
best choice. If they would like to study osteolysis in ATL, they should
choose the RV-ATL cells, which are very osteolytic. The HT1-RV and
TL-Om1 cells represent an intermediate phenotype with or without Tax
expression, respectively. Therefore, these mouse models recapitulate
key interactions between ATL and bone and will be useful for in-
vestigations on the interactions and mechanisms responsible for ATL
bone metastasis.
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